EE403 Cost-Effectiveness Analysis of Nivolumab Compared to Pembrolizumab in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients

Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.651
https://www.valueinhealthjournal.com/article/S1098-3015(22)00852-X/fulltext
Title : EE403 Cost-Effectiveness Analysis of Nivolumab Compared to Pembrolizumab in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00852-X&doi=10.1016/j.jval.2022.04.651
First page :
Section Title :
Open access? : No
Section Order : 10585
Categories :
Tags :
Regions :
ViH Article Tags :